Skip to main content

Table 3 Comparison of JIA with no uveitis and with uveitis (JIAU)

From: Paediatric non-infectious uveitis in Cape Town, South Africa: a retrospective review of disease characteristics and outcomes on immunomodulating treatment

Diagnosis

JIA Total N = 217

JIA no uveitis N = 203

JIAU N = 14

p-value

Median Age months

(IQR)

111

(54–148)

114.5

(59–152)

55

(34–86)

†p = 0.008

Age groups (months) N (%)

 

Odds Ratio 95% CI

 0–84

70 (32.3)

60 (29.6)

10 (71.4)

†p = 0.01

0.46 CI 0.25–0.83

 85–144

73 (33.6)

69 (33.9)

4 (28.6)

p = 0.78

0.71 CI 0.22–2.35

 145–192

60 (27.7)

60 (29.6)

0

†p = 0.01

1.0 CI 0.6–1.7

Female N (%)

135 (62.2)

127 (62.5)

8 (57.1)

p = 0.68

0.78 CI 0.26–2.34

Ancestry N (%)

 Mixed

124 (57.1)

114 (56.2)

10 (71.4)

p = 0.40

0.72 CI 0.39–1.3

 Black African

37 (17.1)

35 (17.2)

2 (14.3)

p = 1.00

1.25 CI 0.27–5.8

 Caucasian

56 (25.8)

54 (26.6)

2 (14.3)

p = 0.53

0.46 CI 0.10–2.1

JIA subtype N (%)

 Oligo-articular

83 (38.3)

73 (35.9)

10 (71.5)

†p = 0.01

4.45 CI 1.35–14.7

 Poly articular RF +

18 (8.3)

18 (8.8)

0

p = 0.61

0.08 CI 0.04–0.13

 Poly articular RF –

43 (19.8)

40 (19.7)

3

p = 1.00

1.05 CI 0.54–2.04

 Psoriatic

16 (7.4)

15 (7.4)

1

p = 1.00

0.99 CI 0.59–1.66

 Systemic Onset JIA

17 (7.8)

17 (8.4)

0

p = 0.61

–

 Enthesitis Related Arthritis

38 (17.5)

38 (18.7)

0

p = 0.14

–

 Undifferentiated

2 (0.9)

2 (1)

0

p = 1.00

–

Lab Parameters N (%)

 ANA tested

147 (67.7)

136 (67)

11 (78.6)

†p < 0.001

33.29 CI 6.83–162.09

 Hep2 Positive

15

10

5

 

 Elisa Positive

15

9

6

 

 RF tested

125 (57.6)

116 (57.1)

9 (64.3)

p = 0.36

–

 Negative

107

98

9

  

 Positive

18

18

0

  

HLA B27 tested

Present

63 (29)

4

62 (30.5)

4

1 (7.1)

0

p = 1.00

–